A technology shaped by pandemic-era controversy is finding quieter, more consequential ground in the oncology clinic. Moderna and Merck's positive phase III results in melanoma mark a turning point — not merely for mRNA science, but for how medicine imagines the relationship between a treatment and the singular body it is meant to heal. The promise of a vaccine built not for millions, but for one patient's specific tumor, asks us to reconsider what personalized care can truly mean.
Personalized mRNA cancer vaccines emerge as promising treatment frontier
Health & Medicine